Display options
Cite
Brennan N, Dehabadi MH, Nair S, et al. Efficacy and safety of bimatoprost in glaucoma and ocular hypertension in non-responder patients. Int J Ophthalmol. 2017;10(8):1251-1254doi: 10.18240/ijo.2017.08.11.
Brennan, N., Dehabadi, M. H., Nair, S., Quartilho, A., Bunce, C., Reekie, I., & Obikpo, R. (2017). Efficacy and safety of bimatoprost in glaucoma and ocular hypertension in non-responder patients. International journal of ophthalmology, 10(8), 1251-1254. https://doi.org/10.18240/ijo.2017.08.11
Brennan, Nicholas, et al. "Efficacy and safety of bimatoprost in glaucoma and ocular hypertension in non-responder patients." International journal of ophthalmology vol. 10,8 (2017): 1251-1254. doi: https://doi.org/10.18240/ijo.2017.08.11
Brennan N, Dehabadi MH, Nair S, Quartilho A, Bunce C, Reekie I, Obikpo R. Efficacy and safety of bimatoprost in glaucoma and ocular hypertension in non-responder patients. Int J Ophthalmol. 2017 Aug 18;10(8):1251-1254. doi: 10.18240/ijo.2017.08.11. eCollection 2017. PMID: 28861351; PMCID: PMC5554844.
Copy Download .nbib Format: NLM
Share it on

Int J Ophthalmol. 2017 Aug 18;10(8):1251-1254. doi: 10.18240/ijo.2017.08.11. eCollection 2017.

Efficacy and safety of bimatoprost in glaucoma and ocular hypertension in non-responder patients.

International journal of ophthalmology

Nicholas Brennan, Mohammad H Dehabadi, Sandhya Nair, Ana Quartilho, Catey Bunce, Ian Reekie, Raal Obikpo

Affiliations

  1. Moorfields Eye Hospital NHS Foundation Trust, London EC1V 2PD, UK.
  2. London North West Healthcare NHS Trust, London HA1 3UJ, UK.
  3. North Middlesex University Hospital NHS Trust, London N18 1QX, UK.
  4. NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London EC1V 2PD, UK.

PMID: 28861351 PMCID: PMC5554844 DOI: 10.18240/ijo.2017.08.11

Abstract

AIM: To establish the efficacy and safety of bimatoprost 0.03% monotherapy in glaucoma and ocular hypertension (OHT) patients with inadequate intraocular pressure (IOP)on current therapy.

METHODS: Pre- and post-switch IOPs were analyzed for 59 consecutive patients who were switched from current therapy to bimatoprost monotherapy between 2011-2015. Demographic information, diagnosis, and any adverse events were recorded. Change in IOP post-pre switch was analyzed using a 2-sided Student's paired

RESULTS: There was a statistically significant mean reduction in IOP at the first follow up visit, which was maintained at subsequent follow up visits for patients regardless of diagnosis, or pre-switch treatment (

CONCLUSION: This is the largest independent data set which supports switching glaucoma patients with poor response to current treatment onto bimatoprost monotherapy before considering other adjuvant medical or more invasive therapy.

Keywords: bimatoprost; glaucoma; latanoprost; ocular hypertension

References

  1. Ophthalmology. 2003 Mar;110(3):609-14 - PubMed
  2. J Ocul Pharmacol Ther. 2003 Jun;19(3):193-203 - PubMed
  3. PLoS One. 2016 Mar 24;11(3):e0151644 - PubMed
  4. Clin Ophthalmol. 2012;6:739-46 - PubMed
  5. Adv Ther. 2006 Jan-Feb;23(1):68-73 - PubMed
  6. Ophthalmology. 2014 Nov;121(11):2081-90 - PubMed
  7. Invest Ophthalmol Vis Sci. 2003 Oct;44(10):4419-26 - PubMed
  8. Br J Ophthalmol. 2007 Jun;91(6):757-60 - PubMed
  9. J Glaucoma. 2009 Oct-Nov;18(8):582-8 - PubMed
  10. Jpn J Ophthalmol. 2006 Mar-Apr;50(2):153-7 - PubMed
  11. J Ocul Pharmacol Ther. 2011 Oct;27(5):499-502 - PubMed
  12. Ther Clin Risk Manag. 2011;7:283-90 - PubMed
  13. Clin Ophthalmol. 2014 May 23;8:1031-8 - PubMed
  14. Clin Ophthalmol. 2014 Mar 27;8:643-52 - PubMed
  15. Adv Ther. 2002 Nov-Dec;19(6):275-81 - PubMed
  16. Am J Ophthalmol. 2000 Oct;130(4):429-40 - PubMed
  17. Ophthalmology. 2005 Dec;112(12):2123-30 - PubMed
  18. Ophthalmology. 2008 May;115(5):790-795.e4 - PubMed
  19. Arch Biochem Biophys. 2004 Jan 15;421(2):175-85 - PubMed
  20. Invest Ophthalmol Vis Sci. 2007 Sep;48(9):4107-15 - PubMed
  21. J Ocul Pharmacol Ther. 2008 Oct;24(5):517-20 - PubMed

Publication Types